PRKAA1 and metabolic dysfunction-associated steatohepatitis: Salidroside (SAL) is also an AMPK agonist that prevents the progression of NASH induced by metabolic stress, inflammation, and other factors by activating AMPK signaling (Hu et al., 2021).